Elyn H Wang1, James B Yu2, Robert Abouassally3, Neal J Meropol4, Gregory Cooper5, Nilay D Shah6, Stephen B Williams7, Christopher Gonzalez8, Marc C Smaldone7, Alexander Kutikov9, Hui Zhu10, Simon P Kim11. 1. School of Medicine, Yale University, New Haven, CT. 2. Department of Radiation Oncology, Yale University, New Haven, CT; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT. 3. Urology Institute, Center of Outcomes and Health Care Quality, University Hospitals Case Medical Center, Cleveland, OH; University Hospitals Case Medical Center, Seidman Cancer Center, University Hospital, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH. 4. University Hospitals Case Medical Center, Seidman Cancer Center, University Hospital, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH. 5. University Hospitals Case Medical Center, Department of Gastroenterology, University Hospital, Cleveland, OH. 6. Division of Health Care Policy & Research, Mayo Clinic, Rochester, MN. 7. Department of Urology, The University of Texas Medical Branch at Galveston, Galveston, TX. 8. Urology Institute, Center of Outcomes and Health Care Quality, University Hospitals Case Medical Center, Cleveland, OH. 9. Department of Surgery, Fox Chase Cancer Center, Philadelphia, PA. 10. Louis Stokes VA, Cleveland, OH. 11. Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT; Urology Institute, Center of Outcomes and Health Care Quality, University Hospitals Case Medical Center, Cleveland, OH; University Hospitals Case Medical Center, Seidman Cancer Center, University Hospital, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH. Electronic address: simkim@me.com.
Abstract
OBJECTIVE: To assess the variation in primary treatment of high-risk prostate cancer (PCa) by different hospital characteristics in the United States. MATERIALS AND METHODS: We used the National Cancer Data Base to identify patients diagnosed with pretreatment high-risk PCa from 2004 to 2011. The primary outcomes were different forms of primary therapy or watchful waiting (WW) across different types of hospitals (community, comprehensive cancer community, and academic hospitals). Multivariable logistic regression analyses were used to test for differences in treatment by hospital type. RESULTS: During the study period, we identified 102,701 men diagnosed with high-risk PCa. Overall, the most common treatment was radical prostatectomy (37.0%) followed by radiation therapy (33.2%) and WW (8.5%). Compared with white men with high-risk PCa, black men had lower adjusted odds ratios (OR) for surgery at comprehensive community (OR: 0.64; P <.001) and academic (OR: 0.62; P <.001) hospitals. Similarly, black men were also more likely to be managed with WW at community (OR: 1.49; P <.001), comprehensive cancer community (OR: 1.24; P <.001), and academic (OR: 1.55; P <.001) hospitals, as well as with radiation therapy at comprehensive cancer community (OR: 1.27; P <.001) and academic hospitals (OR: 1.23; P <.001). CONCLUSION: Disparities in the use of WW and different primary treatments among patients with high-risk PCa persisted across different types of hospitals and over time. Our findings highlight a significant racial disparity in the use of curative therapy for high-risk PCa that should be urgently addressed to ensure that all men with PCa receive appropriate care across all racial groups and cancer care facilities.
OBJECTIVE: To assess the variation in primary treatment of high-risk prostate cancer (PCa) by different hospital characteristics in the United States. MATERIALS AND METHODS: We used the National Cancer Data Base to identify patients diagnosed with pretreatment high-risk PCa from 2004 to 2011. The primary outcomes were different forms of primary therapy or watchful waiting (WW) across different types of hospitals (community, comprehensive cancer community, and academic hospitals). Multivariable logistic regression analyses were used to test for differences in treatment by hospital type. RESULTS: During the study period, we identified 102,701 men diagnosed with high-risk PCa. Overall, the most common treatment was radical prostatectomy (37.0%) followed by radiation therapy (33.2%) and WW (8.5%). Compared with white men with high-risk PCa, black men had lower adjusted odds ratios (OR) for surgery at comprehensive community (OR: 0.64; P <.001) and academic (OR: 0.62; P <.001) hospitals. Similarly, black men were also more likely to be managed with WW at community (OR: 1.49; P <.001), comprehensive cancer community (OR: 1.24; P <.001), and academic (OR: 1.55; P <.001) hospitals, as well as with radiation therapy at comprehensive cancer community (OR: 1.27; P <.001) and academic hospitals (OR: 1.23; P <.001). CONCLUSION: Disparities in the use of WW and different primary treatments among patients with high-risk PCa persisted across different types of hospitals and over time. Our findings highlight a significant racial disparity in the use of curative therapy for high-risk PCa that should be urgently addressed to ensure that all men with PCa receive appropriate care across all racial groups and cancer care facilities.
Authors: Robert Steven Gerhard; Dattatraya Patil; Yuan Liu; Kenneth Ogan; Mehrdad Alemozaffar; Ashesh B Jani; Omer N Kucuk; Viraj A Master; Theresa W Gillespie; Christopher P Filson Journal: Urol Oncol Date: 2017-01-12 Impact factor: 3.498
Authors: Joceline V Vu; Vidhya Gunaseelan; Justin B Dimick; Michael J Englesbe; Darrell A Campbell; Dana A Telem Journal: Surg Endosc Date: 2019-02-14 Impact factor: 4.584
Authors: Talha Shaikh; Elizabeth A Handorf; Joshua E Meyer; Michael J Hall; Nestor F Esnaola Journal: JAMA Oncol Date: 2018-02-08 Impact factor: 31.777
Authors: Justin Xavier Moore; Tomi Akinyemiju; Alfred Bartolucci; Henry E Wang; John Waterbor; Russell Griffin Journal: Cancer Epidemiol Date: 2018-05-25 Impact factor: 2.984
Authors: Justin Xavier Moore; Kendra J Royston; Marvin E Langston; Russell Griffin; Bertha Hidalgo; Henry E Wang; Graham Colditz; Tomi Akinyemiju Journal: Cancer Causes Control Date: 2018-06-19 Impact factor: 2.506
Authors: Ahmedin Jemal; Elizabeth M Ward; Christopher J Johnson; Kathleen A Cronin; Jiemin Ma; Blythe Ryerson; Angela Mariotto; Andrew J Lake; Reda Wilson; Recinda L Sherman; Robert N Anderson; S Jane Henley; Betsy A Kohler; Lynne Penberthy; Eric J Feuer; Hannah K Weir Journal: J Natl Cancer Inst Date: 2017-09-01 Impact factor: 13.506